{"product_id":"staar-ansoff-matrix","title":"STAAR Surgical Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Amsoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis STAAR Surgical Amsoff Matrix Analysis shows the company’s growth options across market penetration, market development, product development, and diversification. This page already includes a real preview of the analysis, so you can review the actual content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA-label 21-45 and -3.0 D to -20.0 D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical uses the U.S. EVO ICL FDA label for adults 21-45 with -3.0 D to -20.0 D myopia, plus astigmatism, to target premium patients who are often poor LASIK candidates. The broad range helps STAAR Surgical convert thin-cornea, dry-eye, and higher-prescription cases that still want elective vision correction. This matters in a high-value niche where every approved diopter band can defend share and keep pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eToric ICL for astigmatism up to 4.0 D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical uses toric ICL for astigmatism up to 4.0 D to raise attach rates inside the same refractive consult, so it is a clear market penetration move. It sells more of the same EVO ICL platform in the same clinics, with no new channel needed. The pitch works best when surgeons trust predictable alignment and rotational stability, because that lowers enhancement risk and makes the add-on easier to adopt.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3 million-plus cumulative ICLs build trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical’s 3 million-plus cumulative Implantable Collamer Lens (ICL) procedures show real-world proof, and that history helps win new cases. In premium vision surgery, surgeons and patients look for long follow-up and peer endorsement, so a large installed base lowers adoption friction. That base also supports word-of-mouth referrals and can help STAAR Surgical turn past use into current share gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e75-country reach deepens share in existing markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSTAAR Surgical Company’s 75-country reach supports market penetration by pushing more cases through existing distributors and refractive surgeons, so share can rise without waiting for new market entry. In FY2025, the edge comes from local training, higher case conversion, and repeat surgeon use, not awareness alone. Where approvals and trained surgeons already exist, STAAR Surgical Company can win share faster and at lower cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2-eye elective workflow and premium pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSTAAR Surgical sells into a cash-pay, elective market, so the 2-eye workflow must prove enough value to support premium pricing. In 2025, the key is conversion, not just awareness: more surgeon adoption, faster consult-to-surgery turns, and better capture of patients who want a LASIK alternative. That fits a high-margin model because even small lifts in conversion can matter more than broad brand spend. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSell outcomes, convenience, and fit.\u003c\/li\u003e\n\u003cli\u003eRaise conversion, not just awareness.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSTAAR Surgical’s EVO ICL gains in a large, underserved refractive market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration in STAAR Surgical’s Amsoff Matrix is about selling more EVO ICL cases into the same refractive channels. The U.S. label spans adults 21–45 with -3.0 D to -20.0 D myopia and astigmatism up to 4.0 D, which helps convert LASIK-unfit patients. Over 3 million ICL procedures and 75-country reach support repeat surgeon use and share gains.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025 use\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA label\u003c\/td\u003e\n\u003ctd\u003e21–45, -3.0 D to -20.0 D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAstigmatism\u003c\/td\u003e\n\u003ctd\u003eUp to 4.0 D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled base\u003c\/td\u003e\n\u003ctd\u003e3M+ ICL procedures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReach\u003c\/td\u003e\n\u003ctd\u003e75 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a concise overview of STAAR Surgical’s growth options across existing and new products and markets\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a quick STAAR Surgical Ansoff Matrix view to simplify growth planning and relieve strategic decision-making pain points.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-2022 U.S. launch opens a new geography\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical’s post-2022 U.S. launch used the same implant family, so it fits market development: one device platform, one new country-level market. By fiscal 2025, growth still depended on surgeon training, center-of-excellence adoption, and patient financing, not a new lens launch. The U.S. adds scale, but conversion is slow because adoption usually starts with a small number of high-volume surgeons and expands from there.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3 Asian markets: China, Japan, Korea\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina, Japan, and Korea form a 1.57 billion-person market, and STAAR Surgical can reuse the same ICL platform there without product redesign.\u003c\/p\u003e\n\u003cp\u003eEast Asia has very high myopia demand and dense refractive-surgery networks, so rollout can scale through surgeon training, channel coverage, and conversion.\u003c\/p\u003e\n\u003cp\u003eThe 2025 focus is market share gain in premium vision correction, not reinvention of the lens.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 growth regions: India and Southeast Asia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIndia (1.46 billion people) and Southeast Asia (about 700 million) are big, underpenetrated private-pay markets for STAAR Surgical's ICL line, where LASIK is not always the best fit. Urban eye-care capacity is rising, and elective vision care demand is growing with higher incomes and more refractive surgery centers. Market development still hinges on local approvals, strong distributors, and surgeon training to convert that demand into durable volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLatin America and Gulf markets add cash-pay centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLatin America and Gulf markets fit STAAR Surgical Amsoff Matrix analysis as geographic expansion: STAAR Surgical can place the same EVO and ICL lens portfolio into more metropolitan refractive centers without changing the core product. This works best in cash-pay clinics serving premium patients, where self-pay demand can support higher procedure prices and faster adoption.\u003c\/p\u003e\n\u003cp\u003eThe play is low on product risk but tied to local economics, doctor referral networks, and clinic density. In markets like Brazil, Mexico, the UAE, and Saudi Arabia, a small set of urban centers can drive early volume before broader rollout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e75-plus cleared markets support wider rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSTAAR Surgical Company's 75-plus cleared markets give it many entry points for the same lens family, so market development can scale country by country instead of betting on one launch. In FY2025, that broad regulatory base helped the company target places where premium refractive surgery can grow faster than local GDP, which supports higher ASPs and repeat procedure use. This staged rollout also spreads regulatory and reimbursement risk across regions. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSTAAR Surgical’s FY2025 Growth Lens: U.S. and Asia Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical’s FY2025 market development stayed a geographic play: the same EVO and ICL platform moved into new country markets, especially the U.S. and Asia. With 75-plus cleared markets, growth came from surgeon training, cash-pay adoption, and clinic density, not a new lens launch. East Asia’s 1.57 billion people, plus India at 1.46 billion and Southeast Asia at about 700 million, give the rollout room.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 cue\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCleared markets\u003c\/td\u003e\n\u003ctd\u003e75+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEast Asia population\u003c\/td\u003e\n\u003ctd\u003e1.57B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndia population\u003c\/td\u003e\n\u003ctd\u003e1.46B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoutheast Asia population\u003c\/td\u003e\n\u003ctd\u003e~700M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eSTAAR Surgical Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual STAAR Surgical Amsoff Matrix Analysis document you’ll receive after purchase—no sample, no placeholders, just the full report. The preview you see here is taken directly from the final file, so what you’re reviewing is exactly what you’ll download. Purchase unlocks the complete, professional version with full detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVO Viva presbyopia lens targets 40-plus patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEVO Viva would move STAAR Surgical Company from a myopia-only story into presbyopia, a much older 40-plus patient pool. That matters because it keeps the same ICL surgical platform but adds a new vision claim, so each surgeon can treat more patients with one system. If adopted broadly, it should widen the age band and lift wallet share per surgeon versus the 2025 myopia-led base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e1-port central design keeps refining fluid flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical can keep refining the EVO central-port design by smoothing fluid flow without changing the core surgical steps. In implanted lenses, even small geometry tweaks can matter because they can affect surgeon adoption and patient comfort, so lower friction can be a real product edge. The product move is narrow but useful: improve the same platform, reduce handling pain, and keep the procedure familiar.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eToric sizing updates can cut vault variability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eToric sizing updates can cut vault variability by improving fit and rotational stability in STAAR Surgical Amsoff Matrix Analysis. Better sizing tools help reduce under-vaulting and over-vaulting, which supports more consistent outcomes across a wider prescription range. In 2025, that kind of repeatable fit matters because surgeons tend to keep using lens systems that save chair time and reduce rework in the same operating rooms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreloaded injector systems shorten 1-step implantation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePreloaded injector systems make STAAR Surgical’s existing lenses easier to place, so they fit product development in the Ansoff Matrix. Smaller, more ergonomic injectors can cut setup time and lower handling risk in the operating room, which improves surgeon experience without changing the core lens.\u003c\/p\u003e\n\u003cp\u003eThis is a practical way to broaden use in an existing market, not a new one.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCataract lens variants extend the ophthalmic menu\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSTAAR Surgical can extend its cataract lens line with more variants, giving surgeons a wider implant menu without leaving ophthalmology. That adjacent move can lift revenue per account because one clinic may buy multiple lens options, not just one SKU. It also fits STAAR Surgical's core eye-care base, so product risk stays closer to known channels and surgeon demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSTAAR Surgical's Low-Risk Expansion: One ICL Platform, More Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical Company’s product development is a low-risk Ansoff move: keep the ICL platform, add EVO Viva for the 40+ presbyopia pool, and improve fit, vault control, and preload handling. In 2025, that can widen surgeon use without changing core channels. One platform, more uses.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eWhat it adds\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEVO Viva\u003c\/td\u003e\n\u003ctd\u003e40+ presbyopia\u003c\/td\u003e\n\u003ctd\u003eMore patients per surgeon\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eToric sizing\u003c\/td\u003e\n\u003ctd\u003eBetter vault fit\u003c\/td\u003e\n\u003ctd\u003eLess rework, steadier outcomes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCataract IOLs add a 2nd surgical market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCataract IOLs give STAAR Surgical Company a second, much larger surgical market: cataract surgery tops 28 million cases a year worldwide, far above elective refractive volumes. That cuts reliance on premium vision correction and opens a broader payer-backed procedure base. The tradeoff is tougher competition from entrenched IOL leaders with deep catalogs and strong surgeon loyalty, so share gains will not be easy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePresbyopia implants open a 40-plus segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePresbyopia implants would target the 40-plus age group, so STAAR Surgical Company would move beyond its core myopia base and sell a new clinical solution to a different patient need. That is true diversification in the Ansoff Matrix, because it adds a distinct use case, not just more volume in the same market. Success depends on proving vision-quality tradeoffs surgeons will accept, since presbyopia-correction studies still show many patients want less glare and fewer halos before switching.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOEM injectors can sell to 3rd parties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTAAR Surgical Company’s implant and injector know-how could be sold as OEM parts to other ophthalmic firms, turning one lens franchise into a broader platform. In Q1 2025, STAAR Surgical Company reported net sales of $77.8 million, so adding third-party injector revenue could help smooth swings in one product line. This move needs tight manufacturing control and strong patent and trade-secret protection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e1 accessory stack around the implant procedure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSTAAR Surgical can diversify by adding surgical accessories, sizing tools, and diagnostic workflows around the implant procedure. That would monetize a wider stack and reach new buyers, while staying close to the core ICL workflow. It is a lower-risk move than entering unrelated medtech markets because it builds on the same surgeon relationships and procedure data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-site manufacturing cuts 1-country risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMulti-site manufacturing reduces single-country risk by spreading lens output across regions, so a shock in one market does not freeze supply. For STAAR Surgical, that matters because sales have been heavily tied to Asia, especially China, where policy or demand swings can hit results fast. A broader sourcing base also helps protect service levels and margins when one or two major markets shift.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSTAAR Surgical Company Bets on Diversification Beyond ICLs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification for STAAR Surgical Company means moving beyond core ICL sales into cataract IOLs, presbyopia implants, OEM parts, and accessories. That spreads revenue across bigger eye-surgery uses and reduces reliance on one demand cycle.\u003c\/p\u003e\n\u003cp\u003eQ1 2025 net sales were $77.8 million, so added product lines could help soften swings. The upside is broader reach; the risk is tougher rivals, regulation, and execution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIOLs\u003c\/td\u003e\n\u003ctd\u003eBigger cataract market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEM parts\u003c\/td\u003e\n\u003ctd\u003eNew revenue stream\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccessories\u003c\/td\u003e\n\u003ctd\u003eHigher workflow share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53646993883478,"sku":"staar-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/staar-ansoff-analysis.webp?v=1778899113","url":"https:\/\/balancedscorecardexamples.com\/products\/staar-ansoff-matrix","provider":"Balanced Scorecard","version":"1.0","type":"link"}